Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens erythropoietin receptor (EPOR), transcript variant 1
Synonyms:
EPO-R
Immunogen
A phospho specific peptide corresponding to residues surrounding Tyrosine 485 of human EpoR was used as an immunogen. The antibody only detects EpoR phosphorylated at Tyrosine 485.
Buffer
Store at -20 C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
Erythropoietin (Epo) is a hematopoietic cytokine that is a potent regulator of the viability, differentiation and proliferation of erythroid progenitor cells (1, 3). Epo acts on its target cells by inducing homodimerization of the erythropoietin receptor (EpoR), thereby triggering intracellular signaling cascades. The EpoR encompasses eight tyrosine motifs on its cytoplasmic tail that have been shown to recruit a number of regulatory proteins (1). EpoR shares conserved features in its extracellular and cytoplasmic domains with other family members of cytokine and growth factor receptors (2). Alterations of the Epo/EpoR system have recently been shown to be involved in the pathogenesis of familial erythrocytosis and polycythaemia vera (PV) (3).
Related Pathway
Cytokine-cytokine receptor interaction
Hematopoietic cell lineage
Jak-STAT signaling pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
